CD8A and neoplasm: Similarly, an anti-tumor vaccine combined with TLR1/2 therapy was found to significantly enhance anti-tumor immunity by decreasing PD-1 expression and inducing antigen-specific CD8 + T cells in a mouse melanoma model [38].